Eagle Pharmaceuticals Company Profile (NASDAQ:EGRX)

About Eagle Pharmaceuticals

Eagle Pharmaceuticals logoEagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). It has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). Its near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EGRX
  • CUSIP:
Key Metrics:
  • Previous Close: $69.97
  • 50 Day Moving Average: $61.94
  • 200 Day Moving Average: $47.94
  • 52-Week Range: $33.02 - $102.48
  • Trailing P/E Ratio: 358.82
  • Foreward P/E Ratio: 14.40
  • P/E Growth: 0.00
  • Market Cap: $1.09B
  • Outstanding Shares: 15,636,000
  • Beta: 1.18
Profitability:
  • Net Margins: 3.45%
  • Return on Equity: 3.44%
  • Return on Assets: 2.48%
Debt:
  • Current Ratio: 3.79%
  • Quick Ratio: 3.61%
Additional Links:
Companies Related to Eagle Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Eagle Pharmaceuticals (NASDAQ:EGRX) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $86.00 (22.91% upside)

Analysts' Ratings History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Show:
DateFirmActionRatingPrice TargetDetails
9/22/2016RBC Capital MarketsReiterated RatingOutperform$78.00 -> $80.00View Rating Details
8/16/2016MizuhoBoost Price TargetNeutral$47.00 -> $65.00View Rating Details
6/13/2016Royal Bank Of CanadaReiterated RatingBuy$78.00View Rating Details
4/7/2016Piper Jaffray Cos.Reiterated RatingOverweight$98.00View Rating Details
1/31/2016William BlairReiterated RatingOutperform$109.00View Rating Details
7/2/2015Cantor FitzgeraldReiterated RatingBuy$95.00 -> $92.00View Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Eagle Pharmaceuticals (NASDAQ:EGRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016        
8/9/2016Q216$0.71$0.80$43.55 million$40.90 millionViewN/AView Earnings Details
5/9/2016Q116$0.46($0.06)$29.07 million$29.60 millionViewN/AView Earnings Details
2/25/2016Q415$0.30$0.07$20.78 million$18.20 millionViewListenView Earnings Details
11/11/2015Q315($0.56)($0.65)$5.07 million$3.30 millionViewListenView Earnings Details
8/11/2015Q215($0.57)($0.53)$4.70 million$6.00 millionViewListenView Earnings Details
5/12/2015Q115$1.47$1.31$3.41 million$36.30 millionViewListenView Earnings Details
2/17/2015($0.49)($0.47)ViewN/AView Earnings Details
12/17/2014Q314($0.49)($0.65)$2.81 millionViewN/AView Earnings Details
8/11/2014Q214($0.37)($0.21)$3.40 million$5.80 millionViewN/AView Earnings Details
5/14/2014Q114($0.26)($0.36)$3.20 million$5.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)
Current Year EPS Consensus Estimate: $3.21 EPS
Next Year EPS Consensus Estimate: $4.86 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.02$0.02$0.02
Q2 20161$0.78$0.78$0.78
Q3 20161$0.99$0.99$0.99
Q4 20161$2.43$2.43$2.43
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Eagle Pharmaceuticals (NASDAQ:EGRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Insider Ownership Percentage: 18.80%
Institutional Ownership Percentage: 95.67%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/21/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$66.17$6,603,435.15View SEC Filing  
9/8/2016Proquest Investments Iv, L.P.Major ShareholderSell70,925$62.50$4,432,812.50View SEC Filing  
8/24/2016Proquest Investments Iv, L.P.Major ShareholderSell28,870$63.00$1,818,810.00View SEC Filing  
8/17/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$61.36$6,123,421.20View SEC Filing  
8/16/2016Proquest Investments Iv, L.P.Major ShareholderSell60,150$61.67$3,709,450.50View SEC Filing  
8/15/2016Proquest Investments Iv, L.P.Major ShareholderSell24,949$60.77$1,516,150.73View SEC Filing  
5/13/2016Proquest Management LlcMajor ShareholderSell17,980$40.72$732,145.60View SEC Filing  
4/1/2016Scott TarriffCEOSell30,765$40.63$1,249,981.95View SEC Filing  
3/15/2016Michael GravesDirectorBuy1,000$56.73$56,730.00View SEC Filing  
2/1/2016Scott TarriffCEOSell18,360$68.08$1,249,948.80View SEC Filing  
12/22/2015Sander A. FlaumDirectorSell13,025$54.81$713,900.25View SEC Filing  
12/1/2015Scott TarriffCEOSell14,050$88.93$1,249,466.50View SEC Filing  
11/2/2015Scott TarriffCEOSell19,339$64.63$1,249,879.57View SEC Filing  
10/1/2015Scott TarriffCEOSell17,878$69.92$1,250,029.76View SEC Filing  
9/1/2015Scott TarriffCEOSell16,245$76.95$1,250,052.75View SEC Filing  
7/1/2015Scott TarriffCEOSell135,710$46.34$6,288,801.40View SEC Filing  
6/16/2015Steven L KrillInsiderSell9,980$81.60$814,368.00View SEC Filing  
2/18/2014Jay MoorinDirectorBuy333,333$15.00$4,999,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Eagle Pharmaceuticals (NASDAQ:EGRX)
DateHeadline
businesswire.com logoEagle Pharmaceuticals Announces “Save the Date” for 2016 Investor Day - Business Wire (press release) (NASDAQ:EGRX)
www.businesswire.com - September 29 at 4:45 PM
thestreet.com logoEagle Pharmaceuticals Announces "Save The Date" For 2016 Investor Day (NASDAQ:EGRX)
www.thestreet.com - September 27 at 4:48 PM
publicnow.com logoEagle Pharmaceuticals Announces “Save the Date” for 2016 Investor Day (NASDAQ:EGRX)
www.publicnow.com - September 27 at 4:48 PM
capitalcube.com logoETF’s with exposure to Eagle Pharmaceuticals, Inc. : September 20, 2016 (NASDAQ:EGRX)
www.capitalcube.com - September 21 at 9:04 AM
News IconSell-side Consensus Sees Eagle Pharmaceuticals, Inc. (NASDAQ ... - Frisco Fastball (NASDAQ:EGRX)
friscofastball.com - September 15 at 6:37 AM
News IconEagle Pharmaceuticals Inc Draws Bearish Attention After Forming ... - Chester News (NASDAQ:EGRX)
www.chesterindependent.com - September 15 at 6:37 AM
law360.com logoKirby McInerney Named Lead Counsel In NJ Securities Row (NASDAQ:EGRX)
www.law360.com - September 13 at 9:39 AM
biz.yahoo.com logoEAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:EGRX)
biz.yahoo.com - September 13 at 9:39 AM
News IconPlacing Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Shares Under the Microscope - National Daily Press (NASDAQ:EGRX)
www.nationaldailypress.com - September 10 at 4:30 PM
fool.com logoWhy Eagle Pharmaceuticals Inc. Flew 38.5% Higher in August - Motley Fool (NASDAQ:EGRX)
www.fool.com - September 10 at 4:30 PM
capitalcube.com logoETF’s with exposure to Eagle Pharmaceuticals, Inc. : September 7, 2016 (NASDAQ:EGRX)
www.capitalcube.com - September 7 at 4:57 PM
investornewswire.com logoCan Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Surprise Analysts This Quarter? - Investor Newswire (NASDAQ:EGRX)
www.investornewswire.com - August 29 at 3:49 PM
News IconCrowd Sentiment & Wall Street Views on Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)? - Post News (NASDAQ:EGRX)
www.kentuckypostnews.com - August 21 at 9:18 AM
finance.yahoo.com logoEAGLE PHARMACEUTICALS, INC. Financials (NASDAQ:EGRX)
finance.yahoo.com - August 18 at 4:49 PM
investornewswire.com logoWill Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Hit $91 Price Target? - Investor Newswire (NASDAQ:EGRX)
www.investornewswire.com - August 18 at 7:25 AM
News IconEagle Pharmaceuticals Inc. (NASDAQ: EGRX) price target raised at Mizuho - BNB Daily (blog) (NASDAQ:EGRX)
www.baseball-news-blog.com - August 16 at 9:59 PM
capitalcube.com logoETF’s with exposure to Eagle Pharmaceuticals, Inc. : August 15, 2016 (NASDAQ:EGRX)
www.capitalcube.com - August 15 at 12:01 PM
capitalcube.com logoEagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:EGRX)
www.capitalcube.com - August 12 at 4:51 PM
4-traders.com logoEAGLE PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (NASDAQ:EGRX)
www.4-traders.com - August 10 at 12:03 PM
fxpips.com logoAfter Hours Big Moving Stocks Update – REN, MWW, HIIQ, CSLT, ALDX, EGRX, MPAA (NASDAQ:EGRX)
www.fxpips.com - August 10 at 12:03 PM
finance.yahoo.com logoEagle Pharmaceuticals Reports Positive Outcome From FDA Meeting For RYANODEX For Exertional Heat Stroke NDA Submission (NASDAQ:EGRX)
finance.yahoo.com - August 9 at 3:27 PM
News IconEagle Pharma Reports Second Quarter 2016 Results (NASDAQ:EGRX)
www.biospace.com - August 9 at 3:27 PM
cnbc.com logoEagle Pharmaceuticals posts 2Q profit (NASDAQ:EGRX)
www.cnbc.com - August 9 at 3:27 PM
biz.yahoo.com logoEAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:EGRX)
biz.yahoo.com - August 9 at 3:27 PM
thestreet.com logoShark Bites: Join the Momentum Parade (NASDAQ:EGRX)
realmoney.thestreet.com - August 9 at 3:27 PM
businesswire.com logoEagle Pharmaceuticals, Inc. Reports Second Quarter 2016 Results - Business Wire (press release) (NASDAQ:EGRX)
www.businesswire.com - August 9 at 7:29 AM
biz.yahoo.com logoQ2 2016 Eagle Pharmaceuticals Inc Earnings Release - Before Market Open (NASDAQ:EGRX)
biz.yahoo.com - August 9 at 7:29 AM
publicnow.com logoEagle Pharmaceuticals, Inc. Reports Second Quarter 2016 Results (NASDAQ:EGRX)
www.publicnow.com - August 9 at 7:29 AM
biz.yahoo.com logoEAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:EGRX)
biz.yahoo.com - August 8 at 4:53 PM
investornewswire.com logoStrong Sell Calls For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX ... - Investor Newswire (NASDAQ:EGRX)
www.investornewswire.com - August 4 at 7:43 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Rosen Law Firm Reminds Eagle Pharmaceuticals, Inc. Investors of Important August 1 Deadline in Class Action - EGRX (NASDAQ:EGRX)
finance.yahoo.com - August 2 at 9:35 AM
capitalcube.com logoEagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : August 1, 2016 (NASDAQ:EGRX)
www.capitalcube.com - August 1 at 4:43 PM
finance.yahoo.com logoEGRX Investors: The Wagner Firm Announces The Filing Of A Securities Class Action On Behalf of Eagle Pharmaceuticals Inc. Investors (NASDAQ:EGRX)
finance.yahoo.com - August 1 at 4:43 PM
ftsenews.co.uk logoEagle Pharmaceuticals Inc (EGRX) Updated Price Targets - FTSE News (NASDAQ:EGRX)
www.ftsenews.co.uk - July 29 at 4:52 PM
prnewswire.com logoUPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds ... - PR Newswire (press release) (NASDAQ:EGRX)
www.prnewswire.com - July 29 at 4:52 PM
finance.yahoo.com logo3-DAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm (NASDAQ:EGRX)
finance.yahoo.com - July 29 at 11:58 AM
finance.yahoo.com logoUPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class … (NASDAQ:EGRX)
finance.yahoo.com - July 29 at 11:50 AM
4-traders.com logoDeadline Upcoming on August 1st in Lawsuit for Investors in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) (NASDAQ:EGRX)
www.4-traders.com - July 29 at 11:50 AM
finance.yahoo.com logoUPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX (NASDAQ:EGRX)
finance.yahoo.com - July 29 at 9:27 AM
investornewswire.com logoCan Shares Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Hit $91? - Investor Newswire (NASDAQ:EGRX)
www.investornewswire.com - July 27 at 10:28 PM
finance.yahoo.com logoINVESTOR NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:EGRX)
finance.yahoo.com - July 26 at 2:35 PM
finance.yahoo.com logoAugust 1 Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)
finance.yahoo.com - July 26 at 12:19 PM
finance.yahoo.com logoAPPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm (NASDAQ:EGRX)
finance.yahoo.com - July 26 at 11:42 AM
finance.yahoo.com logoSHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Lawsuit Involving Eagle Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of August 1, 2016 - EGRX (NASDAQ:EGRX)
finance.yahoo.com - July 26 at 10:06 AM
4-traders.com logoEagle Pharmaceuticals : GPM Reminds Investors of the August 1 Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)
www.4-traders.com - July 25 at 4:49 PM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. to Discuss Second Quarter 2016 Financial Results on August 9, 2016 (NASDAQ:EGRX)
finance.yahoo.com - July 25 at 4:30 PM
finance.yahoo.com logoDEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Eagle Pharmaceuticals, Inc. To Contact The Firm - EGRX (NASDAQ:EGRX)
finance.yahoo.com - July 25 at 3:36 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm (NASDAQ:EGRX)
finance.yahoo.com - July 25 at 2:30 PM
finance.yahoo.com logoGPM Reminds Investors of the August 1 Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)
finance.yahoo.com - July 25 at 12:49 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - TGP (NASDAQ:EGRX)
telanaganapress.com - July 23 at 8:53 AM

Social

Eagle Pharmaceuticals (NASDAQ:EGRX) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff